Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-08-15
2006-08-15
Wang, Andrew (Department: 1639)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
C548S302400, C514S416000, C514S309000
Reexamination Certificate
active
07091356
ABSTRACT:
Imido and Amido substituted alkanohydroxamic acids reduce the levels of TNFa and inhibit phosphodiesterase in a mammal. A typical embodiment is 3-(3-cyclopentyloxy-4-methoxyphenyl)-N-hydroxy-3-phthalimidopropionamide.
REFERENCES:
patent: 4077998 (1978-03-01), Fessler et al.
patent: 4173652 (1979-11-01), Bruins et al.
patent: 4820828 (1989-04-01), Demers et al.
patent: 6214857 (2001-04-01), Muller et al.
patent: 6656964 (2003-12-01), Muller et al.
patent: WO 97/05105 (1997-02-01), None
patent: WO 99/06041 (1999-02-01), None
Edward J. Shannon, et al.; Immunomodulatory Assays To Study Structure-Activity Relationships of Thalidomide; 1997; Abstract.
Steven K. Davidsen, et al.; Inhibitors of TNF-Alpha Synthesis; 1995; Abstract.
Sonja Nikolic, et al.; QSPR and QSAR Study of Phthalimidohydroxamic Acids; 1995; Abstract.
Julija Matijevic-Sosa, et al.; Synthesis and Mitodepressive Activity of Some Phthalimidoalkanehydroxamic Acids; 1993; Abstract.
Judit Telegdi, et al.; Hydroxamic Acids As Organic Catalysts of Enzyme Activity; 1990; Abstract.
L.J. Denis, et al.; Matrix Metalloproteinase Inhibitors: Present Achievements and Future Prospects; 1997; Investigational New Drugs 15:175-185.
Theodore J. Torphy; Phosphodlesterase Isozymes Molecular Targets for Novel Antiasthma Agents; 1998; Am. J. Respir. Crit. Care Med.; vol. 157, pp. 351-370.
B. Naafs, M.D., et al.; Thalidomide Therapy—An Open Trial; Mar. 1985; International Journal of Dermatology; vol. 24; pp. 131-134.
Daniel E. Levy, et al.; Matrix Metalloproteinase Inhibitors: A Structure—Activity Study; 1998; J. Med. Chem.; 41; pp. 199-223.
Mark I. Cockett, et al.; Matrix Metalloproteinases and Metastatic Cancer; Biochem. Soc. Symp. 63, pp. 295-313; Printed in Great Britian.
James B. Summers, et al.; Chapter 13. Matrix Metalloproteinase Inhibitors and Cancer; pp. 131-140.
Mauro M. Teixeira, et al.; Phosphodiesterase (PDE)4 Inhibitors: Anti-Inflammatory Drugs of the Future?; May 1997; TiPS vol. 18; pp. 164-170.
Laura G. Corral, et al.; Selection of Novel Analogs of Thalidomide with Enhanced Tumor Necrosis Factor Alpha Inhibitory Activity; 1996; Molecular Medicine; pp. 1076-1551.
Edward F. Kleinman, et al.; Striking Effects of Hydroxamic Acid Substitution on the Phosphodiesterase Type 4 (PDE4) and TNF-Alpha Inhibitory Activity of Two Series of Rolipram Analogues: Implications for a New Active Site Model of PDE4; 1998; American Chemical Society; 41; pp. 266-270.
Jose Maria Palacios, et al.; Second Messenger Systems as Targets for New Therapeutic Agents: Focus on Selective Phosphodiesterase Inhibitors; 1995; IL FARMACO; 50(12); 819-827.
A.U. De, et al.; Possible Antineoplastic Agents I; Journal of Pharmaceutical Sciences; 1974; Abstract; pp. 262-266.
Von. E. Friderich, et al.; Untersuchungen zum ZNS-Wikprofil von Thalidomid-Analoga; 1982; Arzneim.-Forsch./Drug Res. 32(I), Nr. 6; pp. 613-620. Not Translated.
Claude L. Gillet, et al.; Synthesis and Pharmacological Properties of Substituted Cinnamohydroxamic Acids; Mar. 1970; vol. 13; pp. 211-213.
Douglas H. Steinman, et al.; The Design, Synthesis and Structure-Activity Relationships of A Series of Macrocyclic MMP Inhibitors; 1998; Bioorganic & Medicinal Chemistry Letters 8; pp. 2087-2092.
Michael G. Natchus, et al.; Design and Synthesis of Conformationally-Constrained MMP Inhibitors; 1998; Bioorganic & Medicinal Chemistry Letters 8; pp. 2077-2080.
Slawomir M. Wojtowicz-Praga, et al.; Matrix Metalloproteinase Inhibitors; 1997; Investigational New Drugs 15; pp. 61-75.
Anita E. Yu, et al.; Matrix Metalloproteinases—Novel Targets for Directed Cancer Therapy; Sep. 1997(3); Drugs & Aging; pp. 229-244.
Kuniyoshi Tanaka, et al.; Syntheses and Anti-Inflammatory and Analgesic Activites of Hydroxamic Acids and Acid Hydrazides; 1983; Chem. Pharm. Bull. 31(8); pp. 2810-2819.
Malcolm N. Palfreyman; Phosphodiesterase Type IV Inhibitors as Antinflammatory Agents; 1995; Drugs of the Future 20(8); pp. 793-804.
B. Naafs, M.D., et al.; Thalidomide Therapy; Mar. 1985; International Journal of Dermatology; vol. 24; pp. 131-134.
K. Eger, et al.; Synthesis, Central Nervous System Activity and Teratogenicity of a Homothalidomide; 1990; Arzneim.-Forsch./Drug Res. 40(11) No. 10; pp. 1073-1075.
Catherine Burnouf, et al.; Chapter 10—Phosphodiesterase 4 Inhibitors; Section II—Cardiovascular and Pulmonary Diseases; Doherty, Ed.; pp. 91-109.
George W. Muller, et al.; Structural Modifications of Thalidomide Produce Analogs with Enhanced Tumor Necrosis Factor Inhibitory Activity; 1996; J. Med. Chem. 39; pp. 3238-3240.
Man Hon-Wah
Muller George W.
Jones Day
Lundgren Jeffrey S.
Wang Andrew
LandOfFree
Substituted alkanohydroxamic acids and method of reducing... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted alkanohydroxamic acids and method of reducing..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted alkanohydroxamic acids and method of reducing... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3652181